|
| General Information |
| Business: |
Ritter Pharmaceuticals develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health. Our first novel microbiome modulator, RP-G28, an orally administered, high purity galacto-oligosaccharide, is currently under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby effectively adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
5 |
Founded: |
2004 |
|
| Contact Information |
| Address: |
1801 Century Park East, #1820, Los Angeles, CA 90067, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -3.6 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
RTTR |
| Shares (millions): |
4.0 |
| Price Range: |
$5.00 - $5.00 |
| Est.$ Volume |
$ 20.0 mil |
| Manager / Joint Managers |
Aegis Capital Corp/ Chardan Capital Markets |
| Co Managers |
Barrington Research |
| Expected to Trade |
6/24/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
